Farther Finance Advisors LLC Purchases 50,209 Shares of Pfizer Inc. $PFE

Key Points

• Farther Finance Advisors LLC increased its holdings in Pfizer Inc. by 58.9%, owning a total of 135,499 shares valued at approximately $3.28 million.
• Pfizer's quarterly earnings exceeded expectations, reporting $0.78 per share, compared to consensus estimates of $0.58, with year-over-year revenue growth of 10.3%.
• The company recently announced a quarterly dividend of $0.43 per share, translating to an annualized yield of 7.2% with a payout ratio of 91.49%.

Farther Finance Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 58.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,499 shares of the biopharmaceutical company's stock after acquiring an additional 50,209 shares during the period. Farther Finance Advisors LLC's holdings in Pfizer were worth $3,284,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Gould Capital LLC raised its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth about $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the 1st quarter worth $28,000. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.1%

NYSE PFE traded up $0.02 during trading hours on Monday, reaching $24.05. 67,725,099 shares of the company traded hands, compared to its average volume of 42,502,152. The company has a 50 day moving average of $24.61 and a two-hundred day moving average of $24.18. The stock has a market capitalization of $136.74 billion, a PE ratio of 12.79, a PEG ratio of 0.78 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PFE. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.